FDA PCAC July 2026 Full Docket Guide: BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon & Semax | Clinical Peptide
FDA PCAC July 2026 reviews 7 peptides for 503A status: BPC-157, TB-500, KPV, MOTS-c and more. Category 2 restricts compounding access. Full docket guide.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
The FDA Pharmacy Compounding Advisory Committee (PCAC) is scheduled to convene on July 23–24, 2026, to evaluate seven peptides currently under 503A bulk drug substance review: BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax. The hearing's outcome will directly determine whether each compound may continue to be used by licensed 503A compounding pharmacies or face restriction from bulk compounding channels. Researchers monitoring access to these peptides should review this compound-by-compound summary before the hearing date.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: The FDA PCAC July 2026 hearing will evaluate seven peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax — for 503A Category 1 or Category 2 designation; a Category 2 finding would prohibit their use in bulk compounding by 503A pharmacies, significantly affecting research-grade availability.
What the FDA PCAC hearing is evaluating
The FDA's Pharmacy Compounding Advisory Committee meets periodically to review nominations for the 503A bulk drug substance list — the list that governs which substances may be used as starting materials in patient-specific compounding by traditional compounding pharmacies (as opposed to 503B outsourcing facilities).
Under 21 U.S.C. § 503A, a bulk drug substance must meet one of three criteria to be compounded lawfully:
- It appears on the FDA's positive (Category 1) list, OR
- A physician submits a patient-specific order demonstrating a clinical need not met by commercially available drugs, OR
- It is under active evaluation pending a PCAC recommendation
The July 2026 PCAC docket includes seven peptides whose research-grade availability depends on the committee's Category 1 or Category 2 recommendation. Category 2 would mean the substance may not be used in 503A compounding; Category 1 would allow continued bulk compounding with appropriate pharmacy licensure.
For researchers using compounds sourced from 503A compounding pharmacies, the distinction matters. A Category 2 designation does not ban possession or use of a compound for research purposes; it restricts the compounding pharmacy supply pathway. Compounds may remain available through research chemical suppliers, licensed contract research organizations, or 505(b)(2) investigational channels.
Compound-by-compound docket summary
BPC-157
Full name: Body Protective Compound-157 (pentadecapeptide derived from gastric mucosal proteins)
Current 503A status: Under Review
Research category: Tissue repair, angiogenesis, gastrointestinal healing
BPC-157 has the most robust preclinical evidence on the docket. Studies have investigated its roles in angiogenesis, collagen synthesis, fibroblast activation, and nitric oxide pathway modulation across musculoskeletal, gastrointestinal, and neurological injury models (PMID 41898733). Preclinical data also indicate anti-inflammatory effects including reduced IL-6 and TNF-α expression via NF-κB pathway suppression.
The PCAC's evaluation will weigh this preclinical record against the absence of large-scale human RCTs. Notably, BPC-157 is currently the subject of NCT07437547, a Phase 2 clinical trial investigating subcutaneous administration in acute hamstring injury — a development that may influence the committee's assessment of its investigational trajectory. Researchers can track this trial at the BPC-157 library profile.
What to watch for: Whether the PCAC treats the active Phase 2 trial as a mitigating factor that supports continued research access under 503A, or whether it reinforces the argument that an IND pathway is more appropriate.
TB-500
Full name: Thymosin Beta-4 (TB-500 is a synthetic fragment, often designated TB4 Frag)
Current 503A status: Under Review
Research category: Tissue repair, angiogenesis, musculoskeletal injury
TB-500 has been studied for its actin-binding properties and role in VEGF-mediated angiogenesis. Preclinical literature documents dose-dependent promotion of endothelial cell migration and myogenic differentiation in rodent injury models (PMID 41476424). TB-500 is also a WADA-prohibited substance (Category S2: Peptide Hormones, Growth Factors), meaning it is banned year-round in competitive sport regardless of the 503A outcome.
The PCAC review focuses on the 503A compounding pathway specifically — the compound's WADA status is separate from its compounding eligibility. However, the committee may note the WADA classification as reflecting broader regulatory concern about misuse potential.
What to watch for: How the committee handles the distinction between therapeutic research use and performance-enhancement concerns when WADA prohibition is on the record. Visit the TB-500 library profile for full molecular data.
KPV
Full name: Lys-Pro-Val (tripeptide fragment of α-melanocyte-stimulating hormone)
Current 503A status: Under Review
Research category: Immunomodulatory, gut inflammation, wound healing
KPV has been investigated as an anti-inflammatory agent acting through melanocortin receptor signaling, particularly MC3R and MC4R pathways (PMID 41880199). Preclinical data suggest suppression of TNF-α and IL-6 secretion in stimulated immune cells, with investigated applications in mucosal inflammation and topical wound healing models.
KPV's small molecular weight (342.4 g/mol) and tripeptide structure give it favorable stability characteristics. Its short length also complicates analytical detection, which the committee typically addresses when reviewing compounding eligibility.
What to watch for: Whether the committee focuses on the breadth of preclinical anti-inflammatory data or emphasizes the lack of human clinical trials. The KPV library profile contains the full evidence summary.
MOTS-c
Full name: Mitochondrial Open Reading Frame of the 12S rRNA-c (16-amino acid mitochondria-derived peptide)
Current 503A status: Under Review
Research category: Metabolic, insulin sensitivity, longevity, AMPK activation
MOTS-c is unique on the docket as a peptide encoded by mitochondrial rather than nuclear DNA. Studies have investigated its role in AMPK pathway activation, glucose metabolism, and age-associated metabolic decline (PMID 41945630). Research in rodent models has demonstrated potential exercise-mimetic properties through enhanced insulin sensitivity in aged subjects.
MOTS-c's mechanistic novelty — as a mitochondrial-derived signaling molecule rather than a synthetic analogue of an existing protein — may present the committee with an unusual classification challenge. The compound's AMPK-activating mechanism overlaps with NAD+ research pathways, making it of interest in metabolic aging research programs.
What to watch for: How the PCAC weighs mechanistic novelty against the absence of IND-stage clinical data. A Category 1 designation here would be meaningful for researchers studying mitochondrial biology and metabolic aging. Explore related data at the MOTS-c library profile.
DSIP
Full name: Delta Sleep-Inducing Peptide (nonapeptide: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)
Current 503A status: Under Review
Research category: Neuroendocrine, sleep modulation, stress-axis regulation
DSIP was first isolated in 1974 from rabbit cerebral perfusate and has been investigated in studies examining sleep stage modulation, cortisol rhythmicity, and LH pulse regulation (PMID 39798527; DOI 10.1016/0140-6736(77)92546-1). Neuroendocrine research has documented interactions with the hypothalamic-pituitary axis in stress response attenuation models.
DSIP's short half-life and neuroendocrine profile place it in a research category where institutional biosafety review practices vary. The PCAC will review safety and efficacy literature, with attention to whether existing compounding use has generated any pharmacovigilance signal.
What to watch for: Whether the committee's neuroendocrine safety review generates a Category 2 concern around potential pituitary-axis modulation in off-label compounding contexts.
Epitalon
Full name: Epithalon (tetrapeptide: Ala-Glu-Asp-Gly; pineal gland-derived)
Current 503A status: Under Review
Research category: Anti-aging, telomerase modulation, circadian biology
Epitalon research has centered on telomerase activation and telomere length extension in cellular models. Recent published work documented dose-dependent telomere lengthening in normal epithelial and fibroblast cell lines through hTERT mRNA upregulation and telomerase enzyme activation, with ALT pathway involvement specifically in cancer cell lines (PMID 41240216). The compound has also been investigated in animal models for melatonin modulation and circadian regulation.
The PCAC evaluation will likely focus on whether the telomerase-modulating properties raise concerns in the context of compounding for patient-specific use — particularly given that ALT pathway activation in cancer cells introduces a safety question the committee may probe. For the full molecular and evidence profile, see the Epitalon library page.
What to watch for: Safety concerns about telomerase activation in non-normal cell populations and whether the committee requests additional in vivo cancer safety data before recommending Category 1 status.
Semax
Full name: Semax (heptapeptide analogue of ACTH 4–10: Met-Glu-His-Phe-Pro-Gly-Pro)
Current 503A status: Under Review
Research category: Neuroprotection, cognitive function, BDNF modulation
Semax is the only compound on the docket with an existing regulatory approval — it is approved in Russia for clinical use in stroke and transient ischemic attack settings. Preclinical and limited clinical studies have investigated its effects on BDNF upregulation, dopaminergic and serotonergic modulation, and neuroprotection in Alzheimer's disease models (PMID 41479572). Published work demonstrates amyloid burden reduction in transgenic APPswe/PS1dE9/Blg mice and cognitive performance improvements across multiple behavioral paradigms.
Russia's approval history may be treated by the PCAC as evidence of some degree of safety characterization, though the FDA does not accept foreign regulatory approval as a substitute for IND-stage data. Semax's nasal administration route (the primary delivery method in published studies) is an additional consideration for compounding evaluation. Full compound data are available in the Semax library profile.
What to watch for: Whether the Russian approval history provides a meaningful safety argument, and how the committee treats the neurological mechanism evidence relative to FDA's safety-first framework. Use the peptide finder tool to compare Semax with other neuropeptides currently on the 503A list.
What this changes for research access
A Category 2 designation for any compound would remove it from the 503A bulk drug substance list, meaning licensed compounding pharmacies could no longer compound patient-specific preparations from bulk starting materials. This would not:
- Prohibit researchers from possessing or using the compound obtained through other lawful channels
- Prevent contract research organizations from sourcing compounds through investigational new drug (IND) or research-use-only pathways
- Affect compounds already compounded and dispensed prior to the designation date
A Category 1 designation would allow continued compounding under the standard 503A regulatory framework, maintaining current supply infrastructure for research-adjacent prescription use.
Researchers interested in tracking each compound's status in real time can use the PCAC tracker tool on this site.
Timeline and what's next
| Date | Event |
|---|---|
| July 23–24, 2026 | FDA PCAC meeting — public deliberations |
| Following the meeting | Committee votes; FDA reviews recommendations (typically 6–12 months) |
| Post-review | FDA publishes final 503A Category determination in the Federal Register |
| Effective date | Typically 60–180 days after Federal Register publication |
The comment period for the July 2026 docket closed prior to the hearing. Researchers with unpublished data or institutional input had through the comment window to submit written materials to the FDA docket.
After the July meeting, FDA staff will analyze the PCAC recommendations and publish a proposed rule or determination. This process has historically taken 6–18 months after the hearing. Interim compounding of all seven peptides remains legally permissible until a final designation is published.
External sources
- FDA PCAC July 2026 docket: https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee
- Orrick peptide compounding PCAC analysis: https://www.orrick.com/insights/2026/04/fda-pcac-july-2026-peptide-review
- Frieri Levitt peptide compounding regulatory guide: https://www.frierlevitt.com/resources/peptide-compounding-regulations
Frequently asked questions
Q: What does a 503A Category 2 designation mean for BPC-157 research?
A: A Category 2 designation would prohibit licensed 503A compounding pharmacies from using BPC-157 as a bulk drug substance to compound patient-specific preparations. It would not affect researchers obtaining BPC-157 through research chemical suppliers or IND-approved channels, nor would it terminate NCT07437547, the active Phase 2 clinical trial evaluating the compound in hamstring injury.
Q: When is the FDA PCAC July 2026 meeting scheduled?
A: The FDA Pharmacy Compounding Advisory Committee is scheduled to meet on July 23–24, 2026. Public deliberations will cover all seven compounds on the docket: BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax. The committee's vote is advisory; FDA staff issue the final determination afterward.
Q: Which peptides on the July 2026 PCAC docket have the strongest preclinical evidence record?
A: BPC-157 has the largest body of peer-reviewed preclinical literature among the seven, with studies spanning tissue repair, angiogenesis, and gastrointestinal healing across multiple animal models. TB-500 and Semax also have multi-study preclinical records — TB-500 in angiogenesis and tissue repair, Semax in neuroprotection and cognitive function. MOTS-c and Epitalon have smaller but mechanistically distinct evidence bases.
Q: Is TB-500 banned because of the PCAC review?
A: No. TB-500's WADA prohibition (under Category S2: Peptide Hormones, Growth Factors) is independent of the FDA PCAC review. WADA bans apply to competitive athletes subject to anti-doping testing; the 503A designation governs compounding pharmacy supply pathways. The PCAC review may note TB-500's WADA classification as context but the two regulatory frameworks operate separately.
Q: What happens to Semax compounding if it receives a Category 2 designation?
A: A Category 2 designation would restrict bulk compounding of Semax by 503A pharmacies in the United States. Russian regulatory approval of Semax for stroke-related indications would not override an FDA Category 2 finding. Researchers in the United States could continue to access Semax through research-use channels not governed by 503A compounding rules, or through formal IND applications with the FDA.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.